Trial
NCT03988647
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Stanford University
Collaborators
—
Condition
Merkel Cell Carcinoma
Intervention
Pembrolizumab
Why stopped
Business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-09